Medtronic raises FY27 outlook after reporting strong Q1 growth

Medtronic’s cardiac ablation solutions, a sub-segment of its electrophysiology business, was the strongest performer in Q1 with YoY growth of 29.5%. Medtronic’s cardiac ablation solutions, a sub-segment of its electrophysiology business, was the strongest performer in Q1 with YoY growth of 29.5%. Medtronic’s positive Q1 FY27 results follow its FY26 results which it asserted were its strongest in a decade. Credit: JHVEPhoto/Shutterstock.com Medtronic has reported revenues of around $9.8bn in Q1 of fiscal year 2027 (FY27) driven by double-digit growth across its key business segments, prompting the company to raise its FY27 outlook. With Q1 performance corresponding to year-over-year (YoY)…

Source: Medical Device Network